Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Shares Outstanding: 2010-2025

Historic Shares Outstanding for Altimmune (ALT) over the last 9 years, with Sep 2025 value amounting to $95.6 million.

  • Altimmune's Shares Outstanding rose 34.41% to $95.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.6 million, marking a year-over-year increase of 34.41%. This contributed to the annual value of $72.4 million for FY2024, which is 2.37% up from last year.
  • Altimmune's Shares Outstanding amounted to $95.6 million in Q3 2025, which was up 12.37% from $85.1 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Shares Outstanding registered a high of $95.6 million during Q3 2025, and its lowest value of $38.3 million during Q1 2021.
  • Its 3-year average for Shares Outstanding is $69.9 million, with a median of $71.0 million in 2024.
  • Data for Altimmune's Shares Outstanding shows a peak YoY surged of 149.08% (in 2021) over the last 5 years.
  • Over the past 5 years, Altimmune's Shares Outstanding (Quarterly) stood at $41.0 million in 2021, then climbed by 20.02% to $49.2 million in 2022, then surged by 43.65% to $70.7 million in 2023, then increased by 2.37% to $72.4 million in 2024, then soared by 34.41% to $95.6 million in 2025.
  • Its Shares Outstanding was $95.6 million in Q3 2025, compared to $85.1 million in Q2 2025 and $77.8 million in Q1 2025.